8-K: BridgeBio Reports Strong Q3 Revenue, Positive Phase 3 Data

BridgeBio Pharma announced robust third-quarter 2025 financial results and significant positive clinical trial outcomes for multiple pipeline programs.

Summary

• Total third quarter revenue reached $120.7 million, a substantial increase from $2.7 million in Q3 2024.
• U.S. Attruby net product revenue was $108.1 million, with 5,259 unique patient prescriptions from 1,355 unique prescribers since November 2024 FDA approval.
• Positive topline interim analysis results from FORTIFY (Phase 3 study of BBP-418 for LGMD2I/R9), showing a 1.8x increase in glycosylated DG and an 82% reduction in serum CK.
• Positive topline results from CALIBRATE (Phase 3 study of encaleret for ADH1), with 76% of participants achieving both serum and urine calcium within target ranges.
• The company intends to file New Drug Applications (NDAs) for BBP-418 and encaleret with the FDA in the first half of 2026.
• Ended the quarter with $645.9 million in cash, cash equivalents, and marketable securities.
• Net loss attributable to common stockholders increased to $182.7 million for Q3 2025, compared to $162.0 million for Q3 2024.

Sentiment

Score: 8

Explanation: The filing presents very strong positive clinical trial results for multiple pipeline assets (BBP-418, encaleret) and robust commercial performance for Attruby, indicating significant progress towards becoming a multi-medicine company. While net loss increased, this is largely attributable to commercialization investments and non-cash items, and the company remains well-capitalized. The overall outlook for future approvals and growth is highly positive.

Positives

• Total third quarter revenue significantly increased to $120.7 million from $2.7 million in the prior year.
• Attruby generated $108.1 million in U.S. net product revenue, demonstrating strong commercial launch momentum with 5,259 unique patient prescriptions.
• BBP-418 for LGMD2I/R9 achieved all primary and secondary endpoints in its Phase 3 interim analysis, showing a 1.8x increase in glycosylated DG and an 82% reduction in serum CK.
• Encaleret for ADH1 met all primary and key secondary efficacy endpoints in its Phase 3 study, with 76% of participants achieving target calcium ranges.
• The company is well-capitalized with $645.9 million in cash, cash equivalents, and marketable securities.
• Attruby demonstrated a 49% hazard reduction in cumulative cardiovascular outcomes (CVM or recurrent CVH) at Month 30 in the ATTRibute-CM study.
• BBP-418 showed statistically significant and clinically meaningful improvements in ambulation (100MTT velocity, p<0.0001) and pulmonary function (FVC % predicted, p=0.0071).
• Encaleret was well-tolerated with no discontinuations related to the study drug.

Negatives

• Net loss attributable to common stockholders increased to $182.7 million for the three months ended September 30, 2025, from $162.0 million for the same period in 2024.
• Net loss per share increased to $0.95 for Q3 2025 from $0.86 for Q3 2024.
• Total operating costs and expenses increased to $265.9 million for Q3 2025 from $194.5 million for Q3 2024, primarily due to increased selling, general and administrative (SG&A) expenses for Attruby commercialization.
• Total other income (expense), net, decreased significantly to $(41.3) million for Q3 2025 from $27.5 million for Q3 2024, primarily due to a decrease in gain on deconsolidation of subsidiaries and an increase in noncash interest expense on deferred royalty obligations.

Risks

• Initial and ongoing data from preclinical studies and clinical trials may not be indicative of final data.
• The potential size of target patient populations for product candidates may not be as large as anticipated.
• Future regulatory filings, approvals, and/or sales are not guaranteed, and regulatory agencies may not agree with approval strategies or sufficiency of data.
• The continuing success of collaborations is not assured.
• Ability to obtain additional funding, including through less dilutive sources, is a risk.
• Potential volatility in share price.
• Impacts of current macroeconomic and geopolitical events, including hostilities in Ukraine and in Israel and the Gaza Strip, and increasing rates of inflation and changing interest rates, on business operations and expectations.

Future Outlook

BridgeBio plans to file New Drug Applications (NDAs) for BBP-418 (LGMD2I/R9) and encaleret (ADH1) with the FDA in the first half of 2026, with a Marketing Authorization Application for encaleret to the EMA to follow. The company expects topline results for infigratinib (achondroplasia) in early 2026 and plans to initiate new clinical trials for encaleret in pediatric ADH1 and chronic hypoparathyroidism, and for BBP-418 in pediatric LGMD2I/R9 and LGMD2M/2U in the near term. Data from the Phase 3 portion of the ACCEL 2/3 study in hypochondroplasia is expected in 2026.

Management Comments

• "Attruby's first year on the market has been remarkable, with continued growth across all market segments and strong physician adoption that reflects both the differentiated clinical profile and the trust we're earning within the community."
• "We're seeing meaningful momentum where prescribers are not only initiating more patients on therapy but continuing treatment, underscoring Attruby's real-world impact."
• "Attruby's strong commercial performance continues to validate our model, delivering a potential best-in-class medicine to patients who were historically overlooked and building meaningful momentum across all market segments."
• "We are now seeing that same success echoed in our pipeline with home-run data in both ADH1 and LGMD2I/R9, and we continue to advance one of the broadest and fastest-moving portfolios in genetic medicine."
• "We are not slowing down and continue to be impatient for patients. These milestones reflect our growing scalability and strengthen our conviction that BridgeBio is only beginning to show what's possible as we evolve into a durable, multi-medicine company built for patients with genetic diseases for decades to come."

Industry Context

BridgeBio operates in the genetic diseases biopharmaceutical sector, focusing on rare conditions. The company's commercial success with Attruby and positive Phase 3 data for BBP-418 and encaleret position it as a leader in developing "first approved therapies" and "best-in-class medicines" for urgent, unmet needs in these specialized patient populations. The pipeline advancements suggest a strategy to build a durable, multi-medicine company, leveraging its commercial foundation.

Comparison to Industry Standards

• Attruby (acoramidis) is described as the "first near-complete (90%) transthyretin (TTR) stabilizer" for ATTR-CM, setting a "new standard for CVM outcomes" with a 44% hazard reduction in CVM through 42 months, suggesting a strong competitive profile.
• BBP-418 for LGMD2I/R9, if approved, "could be the first approved therapy for individuals living with LGMD2I/R9, potentially representing the first approval of a therapy for any form of LGMD," highlighting a pioneering role.
• Encaleret for ADH1, if approved, "would be the first therapy indicated for individuals living with ADH1," similarly addressing a critical unmet need.
• Infigratinib for achondroplasia has "previously demonstrated best-in-class improvements in annualized height velocity and upper-to-lower body proportionality" and received Breakthrough Therapy Designation, indicating strong potential compared to other treatments or investigational drugs for short stature conditions.

Related Party Transactions

• Royalty Interest Purchase and Sale Agreement with HealthCare Royalty, a related party, and Blue Owl Capital in June 2025, generating net proceeds of $297.0 million.
• Noncash interest expense on deferred royalty obligations includes related party amounts of $(5,383) thousand for Q3 2025 and $(5,560) thousand for the nine months ended September 30, 2025.
• Accrued and other current liabilities include a related party amount of $1,647 thousand as of September 30, 2025.
• Deferred royalty obligations, net, include a related party amount of $201,242 thousand as of September 30, 2025.
• Repayments of deferred royalty obligations include a related party amount of $(665) thousand for the nine months ended September 30, 2025.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue growth, successful clinical trial outcomes, and a robust pipeline, potentially leading to future approvals and increased market value. Increased net loss and operating expenses could be a concern but are largely tied to growth investments.
• Patients: Significant positive impact with the commercialization of Attruby and the advancement of BBP-418 and encaleret towards potential first-ever approved therapies for LGMD2I/R9 and ADH1, addressing urgent unmet medical needs.
• Prescribers/Healthcare Providers: Increased adoption of Attruby indicates trust in its clinical profile. New potential therapies in the pipeline offer more treatment options for rare genetic diseases.
• Employees: Continued growth and pipeline success suggest job stability and potential for expansion.
• Creditors: The company's strong cash position and revenue growth provide confidence in its ability to meet financial obligations.

Next Steps

• File NDA for BBP-418 with the FDA in the first half of 2026.
• Submit NDA for encaleret to the FDA in the first half of 2026.
• Submit Marketing Authorization Application for encaleret to the European Medicines Agency.
• Share more data on Attruby at the American Heart Association (AHA) Congress in November 2025 and other medical congresses throughout 2026.
• Expect topline results for PROPEL 3 (infigratinib for achondroplasia) in early 2026.
• Initiate clinical studies of BBP-418 in LGMD2I/R9 for individuals less than 12 years of age and in LGMD2M/2U in the near future.
• Initiate a registrational clinical trial of encaleret in pediatric ADH1 in the first quarter of 2026.
• Initiate a Phase 3 study of encaleret in chronic hypoparathyroidism in 2026.
• Expect to fully enroll the Phase 2 portion of the ACCEL 2/3 study (infigratinib for hypochondroplasia) by the end of 2025.
• Expect Phase 2 data for infigratinib in hypochondroplasia in the second half of 2026.

Key Dates

Recommendation

The filing demonstrates significant progress across BridgeBio's commercial and clinical fronts. Attruby's strong revenue growth and physician adoption indicate successful market penetration. More importantly, the "home-run data" from Phase 3 trials for BBP-418 and encaleret, leading to planned NDA submissions in early 2026, represent major de-risking events and potential first-in-class therapies for severe genetic diseases. While the net loss increased, this is largely due to strategic investments in commercialization and R&D, which are necessary for long-term growth. The company's healthy cash position further supports its ability to execute on its pipeline and commercialization plans. These factors collectively point to a strong growth trajectory and significant future value creation, making it an attractive investment.

Keywords

BridgeBio Pharma, BBIO, Attruby, acoramidis, ATTR-CM, BBP-418, LGMD2I/R9, encaleret, ADH1, achondroplasia, infigratinib, hypochondroplasia, genetic diseases, rare diseases, biopharmaceutical, Q3 2025, financial results, clinical trials, FDA, NDA, commercial launch, revenue, net loss, pipeline